UTILITY OF BONE MARROW BIOPSY IN POSITRON EMISSION TOMOGRAPHY-STAGED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
EHA Library, Mark Grech, 266698
PROGNOSTIC SIGNIFICANCE OF SAMHD1 EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
EHA Library, Ioanna Xagoraris, 266699
EFFICACY AND TOXICITY OF INTENSIVE CHEMOTHERAPY REGIMENS IN PRIMARY MEDIASTINAL (THYMIC) LARGE В-CELL LYMPHOMA.
EHA Library, Inga Zavodnova, 266700
AUTOLOGOUS STEM CELL TRANSPLANT IN DIFFUSE LARGE B CELL LYMPHOMA: SIMILAR OUTCOMES AFTER BEAM AND FEAM CONDITIONING REGIMENS
EHA Library, Bruno Loureiro, 266701
SAFETY AND EFFICACY OF ONCE-WEEKLY CARFILZOMIB DOSING IN FRAIL PATIENTS: A SUBGROUP ANALYSIS FROM THE PHASE 3 A.R.R.O.W. STUDY
EHA Library, María-Victoria Mateos, 266996
PEPTIDE VACCINATION AGAINST PD-L1 (IO103) IN MULTIPLE MYELOMA - A PHASE I FIRST IN HUMAN TRIAL
EHA Library, Nicolai Jørgensen, 266997
A PHASE 2 TRIAL OF THE COMBINATION OF IXAZOMIB, THALIDOMIDE AND DEXAMETHASONE (ITD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA - THE AMARC 16-02 TRIAL
EHA Library, Andrew Spencer, 266998
DEEPENING RESPONSES SEEN WITH IXAZOMIB MAINTENANCE POST-AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) ARE ASSOCIATED WITH PROLONGED PROGRESSION-FREE SURVIVAL - ANALYSIS FROM THE TOURMALINE-MM3 STUDY
EHA Library, Hartmut Goldschmidt, 266999
A SEQUENTIAL COHORT STUDY COMPARING KAPPAMAB ALONE TO KAPPAMAB, LENALIDOMIDE AND LOW DOSE DEXAMETHASONE IN KAPPA-RESTRICTED RELAPSED REFRACTORY (RR) MULTIPLE MYELOMA (AMARC 01-16)
EHA Library, Anna Kalff, 267000
TREATMENT CHOICES AND OUTCOMES FOR PATIENTS WITH MULTIPLE MYELOMA AFTER RELAPSE ON LENALIDOMIDE MAINTENANCE THERAPY: RESULTS FROM THE CONNECT® MM REGISTRY
EHA Library, Sundar Jagannath, 267001
THE IMPACT OF A PRIOR MALIGNANCY ON THE DEVELOPMENT OF A SUBSEQUENT MALIGNANCY IN MULTIPLE MYELOMA REVISITED: A COMPETING RISK ANALYSES
EHA Library, Mirian Brink, 267002
CARFILZOMIB AS PART OF A DOSE DENSE, LESS DOSE INTENSE TOTAL THERAPY APPROACH FOR HIGH RISK MYELOMA
EHA Library, Frits van Rhee, 267003
CARFILZOMIB IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS FROM PHASE 3 ASPIRE AND ENDEAVOR
EHA Library, Thierry Facon, 267004
RELATIVE EFFICACY OF APPROVED AND RECENTLY INTRODUCED TREATMENTS FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: A NETWORK META-ANALYSIS
EHA Library, Katja Weisel, 267005
IMPACT OF DIFFERENT MAINTENANCE THERAPY OPTIONS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA AT MD ANDERSON CANCER CENTER
EHA Library, Mohammed Shazly, 267006
PRELIMINARY DATA: PHASE 1B STUDY OF FEASIBILITY/SAFETY OF ISATUXIMAB SHORT DURATION FIXED VOLUME INFUSION IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Library, Saad Usmani, 267007
ASSESSMENT OF THE BURDEN OF DISEASE IN TERMS OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MULTIPLE MYELOMA NOT ELIGIBLE FOR ASCT IN SPAIN: INTERIM ANALYSIS OF QOLMMBUS STUDY
EHA Library, Javier DE LA RUBIA, 267008
CONSOLIDATION WITH A SHORT COURSE OF DARATUMUMAB CAN SIGNIFICANTLY IMPROVE COMPLETE RESPONSE RATES IN PATIENTS WITH AL AMYLOIDOSIS OR LCDD
EHA Library, Efstathios Kastritis, 267009
PRIMARY TREATMENT OF LIGHT CHAIN (AL) AMYLOIDOSIS WITH BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE (VRD)
EHA Library, Efstathios Kastritis, 267010
FLOW-MEDIATED DILATATION AND AORTIC BLOOD PRESSURE PREDICT CARDIOVASCULAR ADVERSE EVENTS DURING CARFILZOMIB TREATMENT: A PROSPECTIVE STUDY IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA.
EHA Library, Efstathios Kastritis, 267011
COMPARATIVE EFFECTIVENESS OF FRONT-LINE TREATMENTS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE TRANSPLANT INELIGIBLE
EHA Library, Thierry Facon, 267012
RESULTS OF PHASE I/II STUDY OF NIVOLUMAB WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS WITH SUBOPTIMAL RESPONSE TO PRIMARY INDUCTION THERAPY
EHA Library, Olga PIROGOVA, 267013
OUTCOMES OF LONG-TERM SURVIVORS WITH ACTIVE MULTIPLE MYELOMA
EHA Library, Brett Grieb, 267014
RECOVERY OF POLICLONAL IMMUNOGLOBULINS AS A PREDICTOR FACTOR OF INCREASED PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA INELIGIBLE FOR ASCT
EHA Library, Julio Davila Valls, 267015
REAL WORLD DATA ON THE EFFICACY AND SAFETY OF DARATUMUMAB FOR TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY AL AMYLOIDOSIS: A MULTI-SITE RETROSPECTIVE STUDY.
EHA Library, Yael C Cohen, 267016
ASSESSMENT OF SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA BY USING MODIFIED RISK STRATIFICATION MSMART 3.0
EHA Library, Sergey Voloshin, 267017
PATIENT REPORTED EXPERIENCE FROM PART 2 OF THE FIRST TIME IN HUMAN STUDY OF THE BCMA ANTIBODY DRUG CONJUGATE GSK2857916 FOR ADVANCED RELAPSED REFRACTORY MULTIPLE MYELOMA (DREAMM-1)
EHA Library, Rakesh Popat, 267018
OUTCOME IN TRANSPLANT ELIGIBLE PATIENTS WITH MULTIPLE MYELOMA IN LATIN AMERICA. AN INTERNATIONAL STUDY OF GELAMM.
EHA Library, Camila PeA a, 267019
IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE (IMCD) IN EUROPE: A HETEROGENEOUS DISEASE TREATED WITH A VARIETY OF AGENTS
EHA Library, Louis Terriou, 267020
RELATIONSHIP BETWEEN COMORBIDITY AND ELIGIBILITY CRITERIA FOR CLINICAL TRIALS IN MULTIPLE MYELOMA. A CRITICAL APPRAISAL.
EHA Library, Ernesto Pérez Persona, 267021
USE OF POMALIDOMIDE-BASED REGIMENS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA IN FOUR EUROPEAN COUNTRIES - FINDINGS FROM PREAMBLE
EHA Library, Philippe Moreau, 267022
WEEKLY CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE UNTIL PROGRESSION IN RELAPSED REFRACTORY MULTIPLE MYELOMA
EHA Library, Cécile Gruchet, 267023
TWICE WEEKLY CARFILZOMIB IS AN ACCEPTED TREATMENT BY PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY: INTERIM RESULTS OF THE CARO STUDY
EHA Library, Wolfgang Knauf, 267024
PROGNOSTIC SIGNIFICANCE OF CD56 EXPRESSION ON BONE MARROW PLASMA CELLS OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS.
EHA Library, Giulia Rivoli, 267025
RESULTS OF THE FREQUENCY AND CAUSES OF DISCONTINUATION OF THE SUCESIVE THERAPEUTIC LINES IN PATIENTS WITH MULTIPLE MYELOMA: REAL LIFE DATA FROM A SINGLE SPANISH CENTER
EHA Library, Ana García Feria, 267026
DARATUMUMAB IS WELL TOLERATED AND INDUCES A RAPID HEMATOLOGICAL RESPONSE IN NON IG-M LIGHT CHAIN AMYLOIDOSIS WITH SEVERE CARDIAC IMPAIRMENT.
EHA Library, Romain Gounot, 267027
CHARACTERISTICS AND TREATMENT OUTCOMES OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) NON-STEM CELL TRANSPLANT (NSCT) PATIENTS IN THE UK, GERMANY, AND FRANCE
EHA Library, Dorothy Romanus, 267028
POMALIDOMIDE 3RD LINE VERSUS 4TH LINE FOR IN EARLY RELAPSED REFRACTORY MULTIPLE MYELOMA
EHA Library, Cécile Gruchet, 267029
INCIDENCE OF NEGATIVE MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA PATIENTS AFTER AUTOLOGOUS STEM CELL TRANSPLANT
EHA Library, Carolina Afonso, 267030
A PHASE 1B/2 STUDY OF SELINEXOR, CARFILZOMIB, AND DEXAMETHASONE (SKD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
EHA Library, Cristina J. Gasparetto, 267031
SURVIVAL OF MULTIPLE MYELOMA PATIENTS DIAGNOSED 1970-2015: REAL-WORLD DATA FROM A SINGLE CENTER
EHA Library, Luis Gerardo Rodríguez-Lobato, 267032
EVOLVING TREATMENT PATTERNS IN NON-STEM CELL TRANSPLANT (NSCT) NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): RESULTS FROM A REAL-WORLD CHART REVIEW IN FRANCE, GERMANY, AND THE UK
EHA Library, Dorothy Romanus, 267033
TREATMENT OUTCOMES OF PATIENTS WITH MONOCLONAL GAMMOPATHY OF CLINICAL SIGNIFICANCE.
EHA Library, Olga Kudyasheva, 267034
POMALIDOMIDE-BASED TREATMENT IN RELAPSED REFRACTORY MULTIPLE MYELOMA: ANALYSIS OF BASELINE CHARACTERISTICS AND SAFETY PROFILE OF PATIENTS WHO DIED IN THE EUROPEAN POST APPROVAL SAFETY STUDY
EHA Library, Barbara Gamberi, 267035
COMPARATIVE EFFECTIVENESS OF TRIPLETS CONTAINING BORTEZOMIB (B), CARFILZOMIB (C), DARATUMUMAB (D), OR IXAZOMIB (I) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN ROUTINE CARE IN THE US
EHA Library, Ajai Chari, 267036
RESULTS FROM A POST-AUTHORIZATION SAFETY STUDY COMPARING LENALIDOMIDE-BASED WITH NON-LENALIDOMIDE-BASED TREATMENT IN TRANSPLANT-INELIGIBILE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
EHA Library, Valerio De Stefano, 267037
HONEUR (HEAMATOLOGY OUTCOMES NETWORK IN EUROPE) - DISTRIBUTED STATISTICS IN A FEDERATED MODEL TO SUPPORT REAL WORLD DATA RESEARCH IN HEMATOLOGY
EHA Library, Alun Passey, 267038
VENETOCLAX FOR THE TREATMENT OF MULTIPLE MYELOMA: OUTCOMES OUTSIDE OF CLINICAL TRIALS
EHA Library, M Hasib Sidiqi, 267039
NEXT-GENERATION SEQUENCING STUDY OF V(D)J REARRANGEMENTS ON NON-CR PATIENTS SHOWING MRD NEGATIVITY BY NEXT-GENERATION FLOW
EHA Library, Sung Min KIM, 267040
THE CRAB SCORE: A SIMPLE PROGNOSTIC TOOL IN MULTIPLE MYELOMA
EHA Library, Helena Bean, 267041
RESULTS OF THE DARATUMUMAB MONOTHERAPY EARLY ACCESS TREATMENT PROTOCOL (EAP) IN PATIENTS FROM EUROPE AND RUSSIA WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
EHA Library, Gordon Cook, 267042
IMMUNE CHECKPOINT (PD-1, PD-L1, PD-L2, AND CTLA-4) EXPRESSION IN PLASMA CELL MYELOMA
EHA Library, Min Young Lee, 267043
THE SIGNIFICANCE OF UNEXPECTED PHARMACOKINETICS OF DARATUMUMAB DURING LONG-TERM MONTHLY TREATMENT FOR MYELOMA
EHA Library, Linda Little, 267044
GCSF ALONE STEM CELL MOBILIZATION IN MULTIPLE MYELOMA PATIENTS CANDIDATES TO HIGH DOSE CHEMOTHERAPY: A MONOCENTRIC RETROSPECTIVE EXPERIENCE.
EHA Library, Stefania Bramanti, 267045
LIVING ALONE WITH MULTIPLE MYELOMA: THE NEXT-GENERATION CHALLENGE
EHA Library, Rafael Rios-Tamayo, 267046
INTEGRATION OF FOUR COLOUR FLOW TO PREDICT RELAPSE/PROGRESSION AND TIME TO NEXT TREATMENT IN MULTIPLE MYELOMA AFTER UPFRONT AUTOLOGOUS STEM CELL TRANSPLANT
EHA Library, Pedro Chorão, 267047
IDENTIFICATION OF THE TRUE HYPERDIPLOID MULTIPLE MYELOMA SUBSET BY COMBINING CONVENTIONAL KARYOTYPING AND FISH ANALYSIS
EHA Library, Gregorio Barilà, 267048
3-WEEKLY DARATUMUMAB-IMID-DEXAMETHASONE IS HIGHLY EFFICACIOUS, HENCE FINANCIALLY AFFORDABLE WITH ENORMOUS ECONOMIC IMPACT FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA IN LESS AFFLUENT COUNTRIES
EHA Library, Chor Sang Chim, 267049
RESULTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS WITH RENAL FAILURE
EHA Library, Ayşe Tülin Tuğlular, 267050
IFN-Α TREATMENT NORMALIZES THE PLATELET COUNTS AND REDUCES QUIESCENT STEM CELLS IN A CALR-DEL52 TRANSGENIC MOUSE MODEL, IN VIVO.
EHA Library, Harini Nivarthi, 267053
SETD2 NON-GENOMIC LOSS OF FUNCTION IN ADVANCED SYSTEMIC MASTOCYTOSIS (SM): PATHOGENETIC AND THERAPEUTIC IMPLICATIONS
EHA Library, Manuela Mancini, 267054
DATA-DRIVEN ANALYSIS OF JAK2V617F KINETICS DURING INTERFERON-ALPHA2 TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA AND RELATED NEOPLASMS
EHA Library, Vibe Skov, 267055
ENHANCED SUPPORT OF MYELOFIBROSIS STEM CELLS IN NEXT GENERATION HUMANIZED MICE
EHA Library, Veronika Lysenko, 267056
A NOVEL ACTIVATING TPOR MUTATION IN ESSENTIAL THROMBOCYTHEMIA POINTS TO AN ACTIVATING EFFECT OF TRYPTOPHAN AND AROMATICS AT THE OUTSET OF THE TRANSMEMBRANE DOMAIN
EHA Library, Gabriel Levy, 267058
PROTEASOME INHIBITOR CARFILZOMIB HAS SYNTHETIC LETHALITY WITH RUXOLITINIB IN MYELOPROLIFERATIVE NEOPLASMS
EHA Library, Simone Claudiani, 267059
BLOCKADE OF TNFR1 RATHER THAN TNFR2 IMPROVES HEMATOCRIT AND REDUCES BLOOD PRO-INFLAMMATORY CYTOKINE LEVELS IN THE VAV1-CRE X JAK2+/V617F MPN MOUSE MODEL
EHA Library, Peter Müller, 267060
THE ROLE OF THE THROMBOPOIETIN RECEPTOR (MPL) IN JAK2V617F-POSITIVE MYELOPLROLIFERATIVE NEOPLASMS
EHA Library, Kira Behrens, 267063
ANALYSIS OF UPR-RELATED GENE EXPRESSION IN CD34+ CELLS FROM PATIENTS WITH PRIMARY MYELOFIBROSIS REVEALS DOWNREGULATION OF UPR GENES AND REDUCTION OF APOPTOSIS
EHA Library, Paolo Catarsi, 267064
LIN-CD133+CD34+CD41+ HSPC REPRESENT A MEGAKARYOCYTE-PRIMED NEOPLASTIC FRACTION IN MPN PATIENTS WITH MYELOFIBROSIS
EHA Library, Vera Köhl, 267065
DISSECTING THE THERAPEUTIC MECHANISM OF RUXOLITINIB IN JAK2V617F MEDIATED MPNS REVEALED AN INHIBITION OF BOTH ONCOGENIC AND NON-ONCOGENIC CELLS BY DOWN REGULATION OF INFLAMMATORY CYTOKINE LEVELS
EHA Library, Sivahari Prasad Gorantla Gorantla, 267066
THE PHARMACOLOGICAL IGF1R-IRS1/2 INHIBITOR OSI-906 REDUCES ERYTHROID PROGENITORS AND INHIBITS STAT3 IN JAK2V617F KNOCKIN-MYELOPROLIFERATIVE NEOPLASM MICE
EHA Library, Jaqueline Fernandes, 267067
THE EFFECT OF HYDROXYUREA ON DNA METHYLATION AND GENE EXPRESSION IN POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA.
EHA Library, Stephania CONTRERAS, 267068
GLI-1, EFFECTOR OF CANONICAL HEDGEHOG SIGNALING PATHWAY, DOES NOT SEEM TO BE DYSREGULATED IN PATIENTS WITH MYELOFIBROSIS
EHA Library, Rajko Kusec, 267069
CURCUMIN INHIBITS PROLIFERATION AND INDUCES APOPTOSIS IN JAK2 MUTATED CELLS THROUGH THE INHIBITION OF JAK2/STAT AND MTORC1 PATHWAYS
EHA Library, Jessica Petiti, 267070
CAG PROMOTER DRIVEN C-MYC OVEREXPRESSION CAUSES RAPIDLY LETHAL CARDIOMYOPATHY
EHA Library, Sarolta Bojtine Kovacs, 267071
RESPONSE TO UP-FRONT AZACITIDINE IN JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML): INTERIM ANALYSIS OF THE PROSPECTIVE EUROPEAN MULTICENTER STUDY AZA-JMML-001
EHA Library, Charlotte M. Niemeyer, 267072
FAVORABLE OVERALL SURVIVAL OF IMETELSTAT-TREATED RELAPSED/REFRACTORY MYELOFIBROSIS PATIENTS COMPARED WITH CLOSELY MATCHED REAL WORLD DATA
EHA Library, Andrew Kuykendall, 267073
MAINTENANCE OF RESPONSE IN LONG-TERM TREATMENT WITH ROPEGINTERFERON ALFA-2B (BESREMI®) VS. HYDROXYUREA IN POLYCYTHEMIA VERA PATIENTS (PROUD/CONTINUATION-PV PHASE III TRIALS)
EHA Library, Heinz Gisslinger, 267074
RISK FACTORS AND OUTCOME OF ACUTE MYELOID LEUKEMIA SECONDARY TO POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT
EHA Library, Barbara Mora, 267075
FEDRATINIB IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASM (MPN)-ASSOCIATED MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX): A REANALYSIS OF THE PHASE 2 JAKARTA-2 STUDY
EHA Library, Claire Harrison, 267076
LONG-TERM FOLLOW UP OF JAK INHIBITOR (JAKI) TREATED PATIENTS WITH MYELOFIBROSIS: IMPACT OF MOLECULAR ENHANCED INTEGRATED SCORING SYSTEMS AND TYPE OF JAKI THERAPY FAILURE ON SURVIVAL
EHA Library, Caroline MCNAMARA, 267077
FAMILIAL OCCURRENCE OF SYSTEMIC AND CUTANEOUS MASTOCYTOSIS IN AN ADULT MULTICENTER SERIES: A REPORT OF 22 CLUSTERED CASES
EHA Library, Ilaria Tanasi, 267078
SECOND PRIMARY MALIGNANCIES IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: REAL WORLD EVIDENCE FROM 215 CONSECUTIVELY TREATED PATIENTS IN LOMBARDY
EHA Library, Margherita MAFFIOLI, 267079
SURVIVAL OUTCOMES IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: A POPULATION-BASED COHORT STUDY IN SWEDEN AND NORWAY
EHA Library, Frida Schain, 267080
INTERFERON ALPHA HAS STRONG ANTI-TUMOR EFFECT IN PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
EHA Library, Patrizia Mondello, 267081
SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH MYELOFIBROSIS (MF) AND ANEMIA (HB <10 G/DL): RESULTS AT WEEK (WK) 24 OF THE REALISE TRIAL
EHA Library, Francisco Cervantes, 267082
CYTOREDUCTION FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA: A SYSTEMATIC REVIEW
EHA Library, Sarah Sloan, 267083
EARLY RESULTS OF A PHASE II STUDY OF COMBINED RUXOLITINIB AND THALIDOMIDE IN PATIENTS WITH MYELOFIBROSIS
EHA Library, Raajit K Rampal, 267084
IMPACT OF CYTOREDUCTIVE DRUGS ON SECOND CANCER IN MYELOPROLIFERATIVE NEOPLASMS
EHA Library, Tiziano Barbui, 267085
IL28B GENE POLYMORPHISMS INFLUENCE ON THE RESPONSIVENESS AND TOLERABILITY OF IFN-Α IN PATIENTS WITH MPN
EHA Library, Marina Stolyar, 267086
EFFICACY AND SAFETY OF ANAGRELIDE IN OLDER PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA
EHA Library, Veronika Buxhofer-Ausch, 267087
MYELOPROLIFERATIVE NEOPLASMS IN KOREAN CHILDREN AND YOUNG ADULTS
EHA Library, Hyoung Soo Choi, 267088
CURRENT PRACTICE IN THE MANAGEMENT OF ESSENTIAL THROMBOCYTEMIA AND POLYCYTHEMIA VERA: A SURVEY FROM THE FRENCH INTERGROUP OF MYELOPROLIFERATIVE NEOPLASMS (FIM) AMONG 120 HEMATOLOGISTS AND INTERNISTS
EHA Library, Guillemette FOUQUET, 267089
ULTRASONOGRAPHY VS RM FOR SPLEEN VOLUME EVALUATION IN MYELOPROLIFERATIVE NEOPLASMS: WHAT YOU NEED TO KNOW.
EHA Library, Novella Pugliese, 267090
NON-HODGKIN LYMPHOMA IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
EHA Library, Kentaro Yoshinaga, 267091
COATED PLATELET FUNCTION IS RELATED TO BLEEDING PHENOTYPE IN PATIENTS WITH INHERITED THROMBOCYTOPENIA
EHA Library, Nanna Brøns, 267092
APPLICATION OF WHOLE EXOME SEQUENCING FOR PATIENTS WITH INHERITED PLATELET DISORDERS
EHA Library, Marian Stevens-Kroef, 267093
PLATELET DISFUNCTION IN NOONAN AND 22Q11.2 DELETION SYNDROMES IN CHILDHOOD
EHA Library, Albert CATALA, 267094
EVALUATION OF COMBINED MEASUREMENT OF IMMATURE PLATELET FRACTION AND SCHISTOCYTES IN PREGNANCY-ASSOCIATED THROMBOTIC THROMBOCYTOPENIC PURPURA AND SEVERE PREECLAMPSIA/ HELLP SYNDROME
EHA Library, Rasha El-Gamal, 267095
INTERLEUKIN-37 REDUCES INFLAMMATION AND IMPAIRS PHAGOCYTOSIS OF PLATELETS IN IMMUNE THROMBOCYTOPENIA
EHA Library, Yajing Zhao, 267097

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.



{$cookies-google-tag-manager-description}


Save Settings